Golden Biotechnology Corp. has made headway with COVID-19 treatment development in more broaden clinical trial patients permitted in inclusion severity as well as future marketing expansion by signing a new international MOU for cooperation and development of the new drugs in 23 European countries. On Aug. 30, 2021, pursuant to clinical trial protocol amended following the recommendation of the approved second interim Data Monitoring Committee review, GoldenBiotech was noticed by CRO that the Food and Drug Administration agreed that its ongoing phase 2 trial of Antroquinonol for treating COVID-19 patients can be extended recruiting from the mild or moderate hospitalized patients to the severe hospitalized COVID-19 patients who need non-invasive oxygen support. The total trial subjects will remain the same, 174 patients in total. The trial recruiting is expedited in full swing covering the USA, Peru and Argentina where the new upheaval pandemic is rampant with highly transmitted SARS-CoV2 variants. Currently, Golden Biotechnology Corp. is the only Taiwanese company that undergoes the formal clinical trial for COVID-19 treatment in multi-national centers and follows the FDA guidance for COVID-19 trials to set the trial as randomized, double-blinded and placebo-controlled study. Antroquinonol is a new small molecule drug with convenient oral administration design and distinguished from other emerging oral treatment drugs for COVID-19 by its multi-functional effects on anti-viral, anti-inflammation and anti-fibrosis characteristics revealed by studies. The new permitted extensive enrollment from mild, moderate to severe patients in the trial will assess the efficacy of recovery rate and prevent the milder COVID-19 patients becoming more severe conditions which will ease the heavy loading of the medical systems. Antoquinonl stands out from current many anti-viral drugs with its ingenious capability of anti-inflammation and liver protection effects which it recruits the COVID-19 confirmed patients consistent with pneumonia from their chest X-ray or computerized tomography scan. The sign of viral pneumonia indicates the inflammation and the tendency of severity which is lack of effective cure and with poor prognosis. People with liver disease are the vulnerable group to COVID-19 infection even the lower and slower antibody protection will produce after their receiving vaccination acc. to the recent studies.